Gabriel Amorim Moreira Alves

Mr. Gabriel Amorim Moreira Alves

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GFGisella Figlioli
Gisella Figlioli
Alessandro SticchiAlessandro Sticchi
Alessandro Sticchi
MCMaria Nefeli Christodoulou
Maria Nefeli Christodoulou
AHAndreas Hadjidemetriou
Andreas Hadjidemetriou
GAGabriel Amorim Moreira Alves
Gabriel Amorim Moreira Alves
DPDaniele Piovani
Daniele Piovani
Background/Objectives: Mitral regurgitation (MR) is the most common left heart valve disease, but its exact prevalence remains uncertain. To estimate the prevalence of MR we conducted a systematic review and meta-analysis of population-based studies. Methods: We searched the Medline/PubMed, Embase, and Scopus databases, in January 2023, for studies reporting or allowing for the calculation of the prevalence of moderate-to-severe MR in the general population. Eligible studies included those using echocardiography or primary care databases from countries with universal healthcare. Studies where echocardiography was performed for medical indications were excluded. Random-effects meta-analysis was used to calculate the pooled estimates. Subgroup and meta-regression analyses were employed to investigate the reasons for heterogeneity. Mixed-model multivariable meta-regression was used to estimate age- and sex-specific prevalence. Results: After screening 13,847 records, we identified 20 eligible studies (22 study populations) including 6,036,691 individuals. The global prevalence of moderate-to-severe MR was 0.67% (95% CI, 0.33−1.11). Prevalence increased greatly with age, and it was estimated to be approximately 0.63% (0.25–1.16) at age 50, 2.85% (1.96–3.90) at 70, and 6.45% (4.17–9.16) by 90 years. North America showed the largest crude prevalence (1.11%; 0.52−1.88), followed by Europe (0.60%; 0.34−0.92), Asia (0.24%; 0.00−0.92), and Africa (0.16%; 0.03−0.37). Differences in prevalence by geographic region and ethnic group were primarily attributable to population age. Prevalence did not differ by sex, study year, or diagnostic criteria. Conclusions: Moderate-to-severe MR is a prevalent condition, particularly among elderly people. With rising life expectancy worldwide, ensuring universal access to interventions will be vital to reduce morbidity and mortality.

15 August 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
GAGabriel Amorim Moreira Alves
Gabriel Amorim Moreira Alves
MTMasatoki Teranishi
Masatoki Teranishi
AOAna Claudia Teixeira de Castro Gonçalves Ortega
Ana Claudia Teixeira de Castro Gonçalves Ortega
FJFrank James
Frank James
AAArosh Shavinda Perera Molligoda Arachchige
Arosh Shavinda Perera Molligoda Arachchige
Substance use disorders (SUDs) remain a major public health challenge, with existing pharmacotherapies offering limited long-term efficacy. Traditional treatments focus on dopaminergic systems but often overlook the complex interplay between metabolic signals, neuroplasticity, and conditioned behaviors that perpetuate addiction. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes and obesity, have recently emerged as promising modulators of reward-related brain circuits. This review synthesizes current evidence on the role of glucagon-like peptide-1 (GLP-1) and its receptor in modulating craving and substance-seeking behaviors. We highlight how GLP-1 receptors are expressed in addiction-relevant brain regions, including the ventral tegmental area (VTA), nucleus accumbens (NAc), and prefrontal cortex (PFC), where their activation influences dopaminergic, glutamatergic, and GABAergic neurotransmission. In addition, we explore how GLP-1 signaling affects reward processing through gut–brain vagal pathways, hormonal crosstalk, and neuroinflammatory mechanisms. Preclinical studies demonstrate that GLP-1RAs attenuate intake and relapse-like behavior across a range of substances, including alcohol, nicotine, and cocaine. Early-phase clinical trials support their safety and suggest potential efficacy in reducing craving. By integrating findings from molecular signaling, neurocircuitry, and behavioral models, this review provides a translational perspective on GLP-1RAs as an emerging treatment strategy in addiction medicine. We propose that targeting gut–brain metabolic signaling could provide a novel framework for understanding and treating SUDs.

24 March 2026 in Chronic Diseases and Translational Medicine
Verified
Journal Article
Open access
GAGabriel Amorim Moreira Alves
Gabriel Amorim Moreira Alves
MTMasatoki Teranishi
Masatoki Teranishi
RMRajendranandini Majumdar
Rajendranandini Majumdar
FKFazal Elahi Khan
Fazal Elahi Khan
MDMohan Dodeja
Mohan Dodeja
FJFrank James
Frank James
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects over 30% of adults worldwide and represents a systemic cardiometabolic disorder in which cardiovascular disease is the leading cause of death. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are uniquely positioned to address this liver–heart axis by combining hepatic disease‐modifying signals with proven cardiovascular risk reduction. This review synthesizes mechanistic, randomized trial, real‐world, and cardiovascular outcome evidence for GLP‐1RAs in MASLD and metabolic dysfunction‐associated steatohepatitis (MASH). In biopsy‐based trials, liraglutide (LEAN) increased steatohepatitis resolution without fibrosis worsening (39% vs. 9% with placebo), while semaglutide demonstrated dose‐dependent resolution (up to 59% vs. 17% in Phase 2). More recently, semaglutide 2.4 mg weekly met both histologic endpoints at interim analysis in F2–F3 MASH (resolution without fibrosis worsening 62.9% vs. 34.3%; fibrosis improvement ≥ 1 stage 36.8% vs. 22.4%), and tirzepatide (SYNERGY‐NASH) achieved high rates of MASH resolution (44%–62% vs. 10%) with concomitant fibrosis improvement signals (up to 51% vs. 30%). Cardiovascular outcome trials demonstrate consistent reductions in major adverse cardiovascular events with GLP‐1RAs, including liraglutide (LEADER), semaglutide (SUSTAIN‐6 and SELECT), and dulaglutide (REWIND). Mechanistically, GLP‐1RAs reduce hepatic lipogenesis and lipotoxicity, attenuate inflammation, improve insulin sensitivity, and modulate gut–brain–liver signaling, with systemic benefits on weight, blood pressure, and atherogenic lipoproteins. Collectively, the evidence supports GLP‐1RAs, particularly semaglutide and tirzepatide, as foundational therapies for MASLD patients with obesity, type 2 diabetes, advanced fibrosis, or heart failure phenotypes. Key gaps include treatment duration, durability of fibrosis benefit, and effectiveness in cirrhosis, requiring long‐term follow‐up.

22 December 2025 in World Journal of Gastrointestinal Pathophysiology
Verified
Journal Article
Open access
AAArosh S Perera Molligoda Arachchige
Arosh S Perera Molligoda Arachchige
AOAna Claudia Teixeira de Castro Gonçalves Ortega
Ana Claudia Teixeira de Castro Gonçalves Ortega
GAGabriel Amorim Moreira Alves
Gabriel Amorim Moreira Alves
Acute appendicitis remains one of the most common causes of emergency abdominal surgery globally. Imaging plays a pivotal role in confirming or excluding the diagnosis and identifying complications that influence management pathways. This narrative review synthesizes contemporary evidence and consensus-based imaging protocols for appendicitis, with a focus on computed tomography, magnetic resonance imaging, and ultrasound. The article explores advanced diagnostic criteria, interpretation challenges, imaging algorithms derived from professional society guidelines, and special considerations including pregnancy and pediatric populations. Clinical practice recommendations by the World Society of Emergency Surgery, European Association of Endoscopic Surgery, American College of Radiology, and Infectious Diseases Society of America are incorporated to frame best practices.

22 March 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
AAArosh Shavinda Perera Molligoda Arachchige
Arosh Shavinda Perera Molligoda Arachchige
GAGabriel Amorim Moreira Alves
Gabriel Amorim Moreira Alves
AZAyça Zal
Ayça Zal
GDGiulia D’Acunto
Giulia D’Acunto
MWMaciej WęGlarz
Maciej WęGlarz
Filippo CademartiriFilippo Cademartiri
Filippo Cademartiri
Background/Objectives: Cardiac magnetic resonance (CMR) imaging at 7 Tesla provides a substantially higher intrinsic signal-to-noise ratio compared with conventional 1.5 T and 3 T systems, potentially enabling higher spatial resolution, improved tissue contrast, and advanced metabolic imaging. However, clinical translation remains limited by technical challenges associated with ultra-high-field operation. This systematic review aimed to synthesize current human in vivo evidence on the feasibility, applications, and methodological limitations of 7-T cardiovascular MRI. Methods: A PRISMA-guided systematic search of PubMed, Cochrane Library, Web of Science, and Scopus was conducted from database inception through January 2025. Studies reporting human in vivo cardiovascular MRI at 7 Tesla were included. Data regarding study design, sample characteristics, imaging applications, feasibility, quantitative findings, and reported limitations were extracted and qualitatively synthesized. Results: Sixty-five studies met inclusion criteria, predominantly small prospective cohorts (mean sample size = 13), largely involving healthy volunteers. Across diverse applications—including coronary MR angiography, cine imaging, valvular assessment, vascular imaging, flow quantification, myocardial tissue characterization, and multinuclear (31P, 23Na, 39K) imaging—7-T CMR was consistently feasible and capable of producing high-quality images. Quantitative ventricular and vascular measurements were generally concordant with lower field strengths. Incremental benefits were most apparent in high-resolution structural imaging and metabolic applications, whereas routine functional and flow assessments showed limited additional advantages. No serious adverse events were reported. Conclusions: Human cardiovascular MRI at 7 Tesla represents a technically feasible research and early translational platform with selective advantages over established field strengths. Further advances in radiofrequency technology, protocol harmonization, and larger disease-focused studies are required to clarify its potential clinical role.

3 February 2026 in Instruments
Verified
Journal Article
Open access
PDF file
GAGabriel Amorim Moreira Alves
Gabriel Amorim Moreira Alves
MDMohan Dodeja
Mohan Dodeja
FKFazal Elahi Khan
Fazal Elahi Khan
MSMary Agnes Szocik
Mary Agnes Szocik
AAArosh Shavinda Perera Molligoda Arachchige
Arosh Shavinda Perera Molligoda Arachchige
The intelligent surgical knife (iKnife), based on rapid evaporative ionization mass spectrometry (REIMS), represents a transformative advance in intraoperative tissue characterization. By integrating mass spectrometry with electrosurgical dissection, the iKnife enables real-time differentiation between cancerous and healthy tissues through molecular fingerprinting of the aerosol generated during cutting. This innovation significantly shortens operative time by eliminating delays associated with conventional histopathological analysis and enhances surgical precision by providing continuous feedback on tissue composition. Since its inception by Zoltán Takáts and colleagues, the iKnife has demonstrated remarkable diagnostic accuracy across multiple cancer types, including breast, ovarian, and colorectal malignancies, with reported sensitivities and specificities > 90% in selected tumour types. Beyond oncology, REIMS technology also shows promise for microbial identification and metabolomic profiling. This review provides a comprehensive overview of the iKnife’s development, underlying principles, clinical validation, and emerging applications, as well as its integration into surgical workflows and the challenges remaining for widespread clinical adoption. Future perspectives include miniaturization, AI-driven spectral interpretation, and expansion into robotic and image-guided surgery.